Indian AI Cancer Platform Gains Spotlight at BRICS Health Summit
iOncology.ai, an AI platform for cancer care, is featured in the BRICS Health Journal, highlighting its potential impact on cancer treatment in emerging economies.
An innovative Indian artificial intelligence platform, iOncology.ai, is gaining international attention at the BRICS Summit, featured in a special issue of the BRICS Health Journal. The technology, developed collaboratively by the All India Institute of Medical Sciences (AIIMS) in New Delhi and the Centre for Development of Advanced Computing (C-DAC) in Pune, is supported by the Ministry of Electronics and Information Technology.
AI-Driven Cancer Care Innovation
iOncology.ai aims to revolutionize cancer care by integrating clinical data to facilitate early detection, risk assessment, treatment planning, and patient data management. The platform is currently undergoing pilot-stage clinical validation to evaluate its performance and utility in real-world clinical settings.
The review titled “Transforming cancer care in emerging economies: India’s AI innovation,” authored by Ashok Sharma and colleagues, examines the potential of AI in enhancing cancer screening, diagnosis, and specialist care access. Dr. Sharma emphasized the opportunity for India to use this platform to reduce cancer care disparities across the Global South, advocating for evidence-based, interoperable solutions tailored to emerging economies.
BRICS Health Journal Spotlight
The BRICS countries, accounting for over 40% of the world's population, face significant cancer challenges, with approximately 9 million new cases and 4.66 million deaths annually. The review highlights disparities in cancer patterns and access to early diagnosis and specialist care within these nations.
iOncology.ai is positioned within India's expanding cancer-control and digital-health framework, which includes population screening, cancer surveillance, and the Ayushman Bharat Digital Mission. The platform utilizes curated clinical, radiological, and histopathological datasets, with plans to incorporate genetic data and integrate with electronic health records.
Future Prospects and Challenges
Despite its promising potential, iOncology.ai has yet to undergo comprehensive clinical validation. It is currently in a research phase, with no peer-reviewed evidence confirming its diagnostic accuracy or clinical effectiveness. Prospective multicentre validation studies are necessary before it can be widely adopted in clinical practice.
Dr. Sharma highlighted the project's focus on empowering clinicians and enabling smarter, more equitable cancer care, particularly in resource-limited settings. Through BRICS collaboration, the aim is to strengthen cancer prevention, early diagnosis, and treatment strategies.